In rhabdoid tumors with SMARCB1 loss-of-function mutations, EZH2 displays a specific dependency which can be exploited using pharmacologic inhibition of EZH2′s enzymatic function [122,123]. Here, EZH2 is linked to rhabdoid tumor.